Effect of application route of the ghrelin analog BIM-28131 (RM-131) on body weight and body composition in a rat heart failure model

Sandra Palus, Stephan Von Haehling, Wolfram Doehner, Rakesh Datta, Jundong Zhang, Jesse Z. Dong, Michael D. Culler, Stefan D. Anker, Jochen Springer

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Chronic heart failure (CHF) remains one of the most challenging diseases in terms of numbers and disease management, particularly so, if the CHF patient develops cardiac cachexia. Ghrelin and its analogs have been suggested to improve body weight and cardiac function in heart failure models and exploratory human clinical studies. However, most ghrelin compounds are peptides and need to be injected several times per day, which affects the quality of life of patients. Here, we compared two application routes, three times daily subcutaneous (sc) injections to continuous infusion using osmotic mini-pumps in a rat model of CHF. Moreover, the effects were also compared to three times daily sc injections of growth hormone (GH). Rats were treated for 28 d. The results show that treatment with 50 or 100 nmol/kg/d BIM-28131 (RM-131) potently induces body weight gain, fat and lean mass compared to placebo. The gain of lean mass was equal to the gain of lean mass in the 2 mg/kg/d GH group and superior to 250 μg/kg/d GH. Both GH and BIM-28131 increased levels of insulin-like growth factor-1 to a similar extent. Little effect was seen on cardiac function; only cardiac output was improved by either high dose BIM-28131 or GH. Overall the effects of BIM-28131 were similar in both application routes.

Original languageEnglish
Pages (from-to)2369-2374
Number of pages6
JournalInternational Journal of Cardiology
Volume168
Issue number3
DOIs
Publication statusPublished - Oct 3 2013

Fingerprint

Ghrelin
Body Composition
Growth Hormone
Heart Failure
Body Weight
Subcutaneous Injections
Cachexia
Somatomedins
Disease Management
Cardiac Output
Weight Gain
Fats
Placebos
Quality of Life
relamorelin
Peptides

Keywords

  • Body composition
  • Chronic heart failure
  • Ghrelin
  • Myocardial infarction
  • Weight gain

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Effect of application route of the ghrelin analog BIM-28131 (RM-131) on body weight and body composition in a rat heart failure model. / Palus, Sandra; Von Haehling, Stephan; Doehner, Wolfram; Datta, Rakesh; Zhang, Jundong; Dong, Jesse Z.; Culler, Michael D.; Anker, Stefan D.; Springer, Jochen.

In: International Journal of Cardiology, Vol. 168, No. 3, 03.10.2013, p. 2369-2374.

Research output: Contribution to journalArticle

Palus, S, Von Haehling, S, Doehner, W, Datta, R, Zhang, J, Dong, JZ, Culler, MD, Anker, SD & Springer, J 2013, 'Effect of application route of the ghrelin analog BIM-28131 (RM-131) on body weight and body composition in a rat heart failure model', International Journal of Cardiology, vol. 168, no. 3, pp. 2369-2374. https://doi.org/10.1016/j.ijcard.2013.01.263
Palus, Sandra ; Von Haehling, Stephan ; Doehner, Wolfram ; Datta, Rakesh ; Zhang, Jundong ; Dong, Jesse Z. ; Culler, Michael D. ; Anker, Stefan D. ; Springer, Jochen. / Effect of application route of the ghrelin analog BIM-28131 (RM-131) on body weight and body composition in a rat heart failure model. In: International Journal of Cardiology. 2013 ; Vol. 168, No. 3. pp. 2369-2374.
@article{e40efa5448824e8ea800c65ad714442d,
title = "Effect of application route of the ghrelin analog BIM-28131 (RM-131) on body weight and body composition in a rat heart failure model",
abstract = "Chronic heart failure (CHF) remains one of the most challenging diseases in terms of numbers and disease management, particularly so, if the CHF patient develops cardiac cachexia. Ghrelin and its analogs have been suggested to improve body weight and cardiac function in heart failure models and exploratory human clinical studies. However, most ghrelin compounds are peptides and need to be injected several times per day, which affects the quality of life of patients. Here, we compared two application routes, three times daily subcutaneous (sc) injections to continuous infusion using osmotic mini-pumps in a rat model of CHF. Moreover, the effects were also compared to three times daily sc injections of growth hormone (GH). Rats were treated for 28 d. The results show that treatment with 50 or 100 nmol/kg/d BIM-28131 (RM-131) potently induces body weight gain, fat and lean mass compared to placebo. The gain of lean mass was equal to the gain of lean mass in the 2 mg/kg/d GH group and superior to 250 μg/kg/d GH. Both GH and BIM-28131 increased levels of insulin-like growth factor-1 to a similar extent. Little effect was seen on cardiac function; only cardiac output was improved by either high dose BIM-28131 or GH. Overall the effects of BIM-28131 were similar in both application routes.",
keywords = "Body composition, Chronic heart failure, Ghrelin, Myocardial infarction, Weight gain",
author = "Sandra Palus and {Von Haehling}, Stephan and Wolfram Doehner and Rakesh Datta and Jundong Zhang and Dong, {Jesse Z.} and Culler, {Michael D.} and Anker, {Stefan D.} and Jochen Springer",
year = "2013",
month = "10",
day = "3",
doi = "10.1016/j.ijcard.2013.01.263",
language = "English",
volume = "168",
pages = "2369--2374",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Effect of application route of the ghrelin analog BIM-28131 (RM-131) on body weight and body composition in a rat heart failure model

AU - Palus, Sandra

AU - Von Haehling, Stephan

AU - Doehner, Wolfram

AU - Datta, Rakesh

AU - Zhang, Jundong

AU - Dong, Jesse Z.

AU - Culler, Michael D.

AU - Anker, Stefan D.

AU - Springer, Jochen

PY - 2013/10/3

Y1 - 2013/10/3

N2 - Chronic heart failure (CHF) remains one of the most challenging diseases in terms of numbers and disease management, particularly so, if the CHF patient develops cardiac cachexia. Ghrelin and its analogs have been suggested to improve body weight and cardiac function in heart failure models and exploratory human clinical studies. However, most ghrelin compounds are peptides and need to be injected several times per day, which affects the quality of life of patients. Here, we compared two application routes, three times daily subcutaneous (sc) injections to continuous infusion using osmotic mini-pumps in a rat model of CHF. Moreover, the effects were also compared to three times daily sc injections of growth hormone (GH). Rats were treated for 28 d. The results show that treatment with 50 or 100 nmol/kg/d BIM-28131 (RM-131) potently induces body weight gain, fat and lean mass compared to placebo. The gain of lean mass was equal to the gain of lean mass in the 2 mg/kg/d GH group and superior to 250 μg/kg/d GH. Both GH and BIM-28131 increased levels of insulin-like growth factor-1 to a similar extent. Little effect was seen on cardiac function; only cardiac output was improved by either high dose BIM-28131 or GH. Overall the effects of BIM-28131 were similar in both application routes.

AB - Chronic heart failure (CHF) remains one of the most challenging diseases in terms of numbers and disease management, particularly so, if the CHF patient develops cardiac cachexia. Ghrelin and its analogs have been suggested to improve body weight and cardiac function in heart failure models and exploratory human clinical studies. However, most ghrelin compounds are peptides and need to be injected several times per day, which affects the quality of life of patients. Here, we compared two application routes, three times daily subcutaneous (sc) injections to continuous infusion using osmotic mini-pumps in a rat model of CHF. Moreover, the effects were also compared to three times daily sc injections of growth hormone (GH). Rats were treated for 28 d. The results show that treatment with 50 or 100 nmol/kg/d BIM-28131 (RM-131) potently induces body weight gain, fat and lean mass compared to placebo. The gain of lean mass was equal to the gain of lean mass in the 2 mg/kg/d GH group and superior to 250 μg/kg/d GH. Both GH and BIM-28131 increased levels of insulin-like growth factor-1 to a similar extent. Little effect was seen on cardiac function; only cardiac output was improved by either high dose BIM-28131 or GH. Overall the effects of BIM-28131 were similar in both application routes.

KW - Body composition

KW - Chronic heart failure

KW - Ghrelin

KW - Myocardial infarction

KW - Weight gain

UR - http://www.scopus.com/inward/record.url?scp=84885596263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885596263&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2013.01.263

DO - 10.1016/j.ijcard.2013.01.263

M3 - Article

C2 - 23465234

AN - SCOPUS:84885596263

VL - 168

SP - 2369

EP - 2374

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 3

ER -